0.00Open0.40Pre Close0 Volume0 Open Interest9.50Strike Price0.00Turnover2435.05%IV-25.34%PremiumDec 13, 2024Expiry Date2.24Intrinsic Value100Multiplier-22DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9071Delta0.4725Gamma18.15Leverage Ratio-30.4984Theta0.0000Rho-16.46Eff Leverage0.0000Vega
Altimmune Stock Discussion
$Altimmune (ALT.US)$
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
Altimmune (Nasdaq: ALT) presented new data from its 12-week Phase 1b trial of pemvidutide in MASLD patients at The Liver Meeting®.
The study demonstrated that weekly subcutaneous doses of pemvidutide significantly reduced inflammatory lipids and showed promising effects on cardiovascul...
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
Will a partner be announced or are the rumours true a buy out is eminent..!
No comment yet